SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing heightened volatility and intense trader interest as it joins the S&P 500 index, a move that is triggering mandatory institutional buying and significant market-making activity. The community remains sharply divided, with bulls pointing to the company's critical role in the AI optics supply chain and Nvidia's strategic investment, while bears warn of stretched valuations and risks stemming from shifting industry preferences toward copper technologies.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest following the major regulatory approval of its Alpha DaRT cancer treatment in Japan, a key milestone that serves as a global validator for its oncology platform. The community is actively discussing the company's strong clinical trial progress, robust cash position, and the potential for upcoming milestones to drive the stock toward its analyst-set price targets.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is capturing significant community attention as it secures strategic government contracts and deepens its collaboration with NVIDIA, leading investors to view it as a compelling, undervalued alternative to other quantum stocks. While some express frustration with recent price volatility and de-SPAC pressure, many are actively accumulating shares based on a long-term conviction in the companys debt-free balance sheet and its pivotal role in national security and AI integration.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently under pressure as investors weigh recent reports of large-scale layoffs against concerns over massive AI infrastructure spending and looming legal challenges. Community sentiment is sharply divided between long-term believers citing the company's valuation and dominant advertising position, and skeptical traders who view recent price action as a technical breakdown signaling further downside risk.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth Inc is seeing significant volatility as investors debate the impact of potential federal funding scrutiny and legal challenges surrounding the company's IP and leadership. Despite the uncertainty, the community remains heavily focused on the stock's role in domestic supply chain security, with many traders accumulating shares during the dip in anticipation of production updates.

OpenAI pioneers large-language models like GPT and DALL·E, enabling advanced AI applications. Their research emphasizes both cutting-edge capability and responsible deployment strategies.

OpenAI PreStocks

Community sentiment regarding OpenAI is heavily polarized, with active discussions focusing on both its leadership in AI traffic and the rise of speculative, unofficial crypto assets claiming to provide investment exposure. Investors are also scrutinizing the company's massive capital expenditure requirements and the potential long-term impact of its partnerships on the financial health of major corporate collaborators.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors react to a strong quarterly report featuring an 18th consecutive earnings beat, positive GAAP net income, and aggressive guidance, with the community actively debating the company's competitive position against The Trade Desk and its long-term potential as an AI-driven marketing powerhouse. Despite broader software sector volatility, bullish sentiment remains high as investors highlight the firm's expanding Fortune 100 client base and its ongoing share buyback program as evidence of institutional value.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is facing significant volatility as investors debate the viability of the company's turnaround plan, balancing recent traffic improvements against margin pressures and intense competition from faster, value-oriented rivals. The community remains deeply divided, with some betting on a long-term recovery under new leadership while others highlight declining brand loyalty and store closures as indicators of structural trouble.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney Co. is in the spotlight as investors react to the appointment of Parks chief Josh D'Amaro as the new CEO, succeeding Bob Iger in a move aimed at revitalizing long-term stock performance. While the community is actively debating the company's future strategy, leadership transition, and ongoing cost-cutting efforts, sentiment remains mixed between those seeking a turnaround and skeptics wary of the stock's recent performance.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is experiencing intense downward pressure as institutional investors and the trading community grapple with a broader sector rotation away from software and cybersecurity, exacerbated by speculative concerns regarding the impact of new AI-driven coding tools. While bullish investors argue the sell-off is a fundamental decoupling and a prime buying opportunity for a SASE leader, the stock faces consistent technical selling and heightened short interest from those betting on continued valuation compression.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

<ul class="summary-bullets"><li>While the patent was granted in September 2025, it had to pass a 6-month opposition period.</li><li>The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer.</li><li>AIM is seeking an orphan drug designation in Japan for its treatment.</li></ul>Shares of AIM ImmunoTech Inc (AIM) gave up some of its pre-market gains and was up more than 60% on Wednesday, after the company said that a Japanese patent using its proprietary Ampligen in combination with checkpoint inhibitors to treat cancer was fully approved in the country.While the patent was granted in September 2025, it had to pass a 6-month opposition period, AIM said. The patent, which expires in 2039, spans multiple cancer types, including pancreatic cancer. The company holds similar patents in the U.S. and the Netherlands.AIM, which already holds orphan drug designations for pancreatic cancer in the U.S. and Europe, also plans to seek a similar designation in Japan.<h2 class="st-heading-2">DURIPANC Study Update</h2>Earlier this month, AIM ImmunoTech partnered with Thermo Fisher Scientific’s PPD clinical research unit to design a planned Phase 3 trial of Ampligen for late-stage pancreatic cancer.&nbsp;The company also highlighted encouraging results from its ongoing DURIPANC study, including improvements in progression-free and overall survival. The trial is being conducted in collaboration with AstraZeneca and Erasmus Medical Center."Based on the success so far, as well as anticipated final patient enrollment later this year, we believe it is now time to start mapping out the next steps for AIM’s development of Ampligen as a therapy for pancreatic cancer," said CEO Thomas K. Equels."AIM’s scientific team will work closely with Thermo Fisher’s experts in the design of a Phase 3 study and we look forward to their expertise and guidance in this critical endeavor."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to 'extremely bullish' from 'bearish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/AIMS_jpg_04ac5ff737.webp" alt="AIMS.jpg">One user said the RSI has cooled and its time for the next leg of the rally.<stembedurl>https://stocktwits.com/Chessdoc/message/647888049</stembedurl>Year-to-date, the stock has climbed 1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Why Did AIM Stock Jump 60% Today?

The company said that a patent using its proprietary cancer treatment method was fully approved in Japan.

Equity

Are Medical Stocks Lagging  AIM ImmunoTech (AIM) This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Cullinan Therapeutics (CGEM) have performed compared to their sector so far this year.

Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?

Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.

Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions

HNST, BROS, AIM, MASI, and CTSH are spotlighted as top-ranked stocks with rising P/E ratios and strong earnings momentum.

Bet On 5 Top-Ranked Stocks With Rising P/E 

Tap these five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are The Honest Company, Dutch Bros, AIM ImmunoTech, Masimo and Cognizant Technology Solutions.

All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy

AIM ImmunoTech (AIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

This account has been verified as an official AIM representative.

Verified Account

AIM Immunotech

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

AIM
AIM ImmunoTech

Feed

News

Sentiment

Fundamentals

Info

Latest AIM News

AIMAIM ImmunoTech